X4 Pharmaceuticals (XFOR) Other Non-Current Liabilities (2017 - 2025)

X4 Pharmaceuticals has reported Other Non-Current Liabilities for 9 years, with the latest figure at $525000.0 in Q4 2025.

• For the quarter ending Q4 2025, Other Non-Current Liabilities fell 96.18% year-over-year to $525000.0; the trailing twelve-month figure through Dec 2025 stood at $525000.0 (down 96.18% YoY), and the FY2025 full-year result was $525000.0, down 96.18% from the prior year.
• Other Non-Current Liabilities for Q4 2025 stood at $525000.0, down from $959000.0 in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $29.4 million in Q1 2024, with the low at $283000.0 in Q2 2025.
• Historically, Other Non-Current Liabilities has averaged $6.3 million across 5 years, with a median of $1.1 million in 2023.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities jumped 2621.85% — and 2025, when it sank 96.93%.
• X4 Pharmaceuticals' Other Non-Current Liabilities stood at $496000.0 in 2021, then surged by 4565.52% to $23.1 million in 2022, then plunged by 32.23% to $15.7 million in 2023, then fell by 12.29% to $13.8 million in 2024, then sank by 96.18% to $525000.0 in 2025.
• The last three Other Non-Current Liabilities figures came in at $525000.0 (Q4 2025), $959000.0 (Q3 2025), and $283000.0 (Q2 2025), per Business Quant data.